Adverse effects of anticancer agents that... [Nat Rev Clin Oncol. 2009] - PubMed

loading

Review The role of antiangiogenesis therapy: bevacizumab and beyond. [Clin Transl Oncol. 2009]
Review The role of antiangiogenesis therapy: bevacizumab and beyond.
Cortés-Funes H. Clin Transl Oncol. 2009 Jun; 11(6):349-55.
Review Mechanisms of adverse effects of anti-VEGF therapy for cancer. [Br J Cancer. 2007]
Review Mechanisms of adverse effects of anti-VEGF therapy for cancer.
Kamba T, McDonald DM. Br J Cancer. 2007 Jun 18; 96(12):1788-95. Epub 2007 May 22.
Review Drug insight: VEGF as a therapeutic target for breast cancer. [Nat Clin Pract Oncol. 2007]
Review Drug insight: VEGF as a therapeutic target for breast cancer.
Schneider BP, Sledge GW Jr. Nat Clin Pract Oncol. 2007 Mar; 4(3):181-9.
Cardiovascular toxicity of new agents. [Clin Adv Hematol Oncol. 2008]
Cardiovascular toxicity of new agents.
Maitland ML. Clin Adv Hematol Oncol. 2008 Sep; 6(9):657-9.
Review Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. [Clin Cancer Res. 2007]
Review Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
Rini BI. Clin Cancer Res. 2007 Feb 15; 13(4):1098-106.

Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies. [BMC Syst Biol. 2011]
Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies.
Finley SD, Engel-Stefanini MO, Imoukhuede PI, Popel AS. BMC Syst Biol. 2011 Nov 21; 5:193. Epub 2011 Nov 21.
A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor. [J Exp Med. 2011]
A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor.
Chabot S, Jabrane-Ferrat N, Bigot K, Tabiasco J, Provost A, Golzio M, Noman MZ, Giustiniani J, Bellard E, Brayer S, et al. J Exp Med. 2011 May 9; 208(5):973-86. Epub 2011 Apr 11.
Review Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review. [Oncologist. 2011]
Review Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review.
Keefe D, Bowen J, Gibson R, Tan T, Okera M, Stringer A. Oncologist. 2011; 16(4):432-44. Epub 2011 Mar 25.

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Adverse effects of anticancer agents that target the VEGF pathway.
Adverse effects of anticancer agents that target the VEGF pathway.
Nat Rev Clin Oncol. 2009 Aug ;6(8):465-77. Epub 2009 Jul 7 .

PubMed
Evaluation of nanoparticle immunotoxicity.
Evaluation of nanoparticle immunotoxicity.
Nat Nanotechnol. 2009 Jul ;4(7):411-4. Epub 2009 Jun 28 .

PubMed
Adjuvant treatment of pancreatic cancer in 2009: where are we? Highlights from t...
Adjuvant treatment of pancreatic cancer in 2009: where are we? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
JOP. 2009 Jul 6 ;10(4):373-7.

PubMed
Calcium phosphate nanoparticles for the transfection of cells.
Calcium phosphate nanoparticles for the transfection of cells.
Biomed Mater Eng. 2009 ;19(2-3):241-7.

PubMed
An unusual case of Munchausen syndrome by proxy.
An unusual case of Munchausen syndrome by proxy.
Aust N Z J Psychiatry. 1991 Sep ;25(3):422-5.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

PubMed